(Q39729571)

14 September 2017

title

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. (English)

1 reference

14 September 2017

1 reference

1 reference

Pramila Paudyal

1

1 reference

14 September 2017

Bishnuhari Paudyal

2

1 reference

14 September 2017

Hirofumi Hanaoka

3

1 reference

14 September 2017

Noboru Oriuchi

4

1 reference

14 September 2017

Yashuhiko Iida

5

1 reference

14 September 2017

Hiroki Yoshioka

6

1 reference

14 September 2017

Hideyuki Tominaga

7

1 reference

14 September 2017

Satoshi Watanabe

8

1 reference

14 September 2017

Shigeki Watanabe

9

1 reference

14 September 2017

Noriko S Ishioka

10

1 reference

14 September 2017

Keigo Endo

11

1 reference

14 September 2017

publication date

22 December 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

101

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

1045-1050

1 reference

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

HER2/neu expression in malignant lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Trastuzumab and breast cancer: developments and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Preclinical characterisation of 111In-DTPA-trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

PET versus SPECT: strengths, limitations and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Positron emission tomography scanning for the diagnosis and management of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Clinical applications of PET in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Efficient production of high specific activity 64Cu using a biomedical cyclotron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

Cancer prevalence in European registry areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01480.X

10.1111/J.1349-7006.2010.01480.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference